SBIR/STTR Research Award

Cell-free Biosensor for the Detection of Pathogens

Award identifier ae61c2b4057effdf8468a9f5ae0597fff57d91e56d604df85486bbf1b89ea289Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INTEGRAL MOLECULAR INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
DY9KSWE8EJB8
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Biosensors capable of detecting infectious agents, and/or of detecting a serological reaction in people potentially exposed to dangerous pathogens, are fundamental to rapid biodefense screening and response processes. Biosensors based on the signaling properties of membrane proteins in living cells are being increasingly developed and used to detect pathogens, but are limited by the stringent handling requirements of living cells. The ability to retain membrane proteins in their native structure within a cell-free environment could enable new types of bio-mimetic detectors to be created that exploit the cell's natural detection mechanisms but without the inherent limitations of living cell assays. The need for novel detection methods that can detect antibody responses to pathogens and, in a revised format, biodefense pathogens themselves, is exemplified by Dengue virus (DEN), a category A biodefense pathogen that results in 100 million cases of DEN related illness annually. DEN exists as four major serotypes, and their distinction is important because sequential exposure to different serotypes increases the likelihood of developing dengue hemorrhagic fever. For such pathogens, characterizing not only the magnitude, but also the breadth, persistence, and specificity of the humoral response is an important component of evaluating candidate vaccines, and understanding pathogenesis in infected individuals. Thus, in addition to biodefense detection, the availability of a rapid, in-field sensor that can detect antibodies against such pathogens could aid in the development and administration of vaccines in endemic regions. The commercial product that will result from this proposal will be a nanometer-scale, cell-free assay system for the detection of pathogen antigens and antibodies present in biological or environmental samples.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

48 SBIR/STTR records share this UEI (2002–2025). Reported award amounts total $32,839,788. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.